Pfizer halts study of lymphoma drug unlikely to help survival

May 20, 2013 10:01 PM

4 0

Pfizer halts study of lymphoma drug unlikely to help survival

(Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival.

Pfizer said it would continue to study the experimental drug, inotuzumab ozogamicin, in other hematologic cancers.

Read more

To category page

Loading...